Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Accelerate Global Commercial Expansion
1.7.2026 12:01:00 CEST | Business Wire | Press Release
Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dr. Hubert Scholze as Chief Business Officer (CBO), effective July 1, 2026.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701630118/en/
Dr. Hubert Scholze, Chief Business Officer, Rezon Bio
As a member of Rezon Bio’s Executive Leadership Team, Dr. Hubert Scholze will lead the company’s commercial functions, overseeing Business Development, Market Intelligence, Global Marketing, Proposal Management and Project Management. Hubert Scholze, PhD will be responsible for Rezon Bio’s commercial strategy, strengthening strategic partnerships, supporting the company’s continued international growth, and ensuring a seamless client experience from initial engagement to program execution.
His appointment comes at pivotal moment for Rezon Bio as the company continues to strengthen its integrated biologics CDMO offering, expanding its global commercial footprint while investing in the capabilities, expertise and partnerships needed to support biosimilars and novel biologics programs from early development to commercial manufacturing.
Dr. Hubert Scholze brings more than 25 years of experience spanning biologics manufacturing, operations and global business development across the pharmaceutical and CDMO industries. Prior to joining Rezon Bio, he led Global Business Development for Catalent’s Core Biologics division, overseeing commercial activities for integrated mammalian drug substance and sterile drug product development and manufacturing services.
“Hubert brings a unique combination of manufacturing expertise, commercial leadership and a deep understanding of the biologics industry and client needs,” said Dr. Adriana Kiędzierska-Mencfeld, Chief Executive Officer (CEO) of Rezon Bio. “His leadership will strengthen how we integrate commercial strategy, scientific excellence and operational execution to deliver greater value for our clients as our organization enters the next phase of growth.”
“I am excited to join Rezon Bio at such an important moment in the company’s journey,” said Dr. Scholze. “What attracted me the most is the proven track record, strong scientific and manufacturing expertise, and talented people who are passionate about delivering for their clients. Combined with a clear ambition for international growth, this creates a strong foundation for the future. I look forward to working with our teams and clients to build long-term partnerships, expand our global presence, and help bring innovative biologic therapies to patients worldwide.”
Dr. Scholze began his career at Boehringer Ingelheim in Vienna, where he held leadership positions in biologics manufacturing, including Unit Head of a large-scale microbial fermentation facility and Manufacturing Director. After several years in manufacturing, he transitioned into sales and business development, taking on roles of increasing responsibility at leading pharmaceutical and biologics CDMO organizations, including Aenova Group and Catalent. Throughout his career, he has partnered with emerging biotech companies and global pharmaceutical organizations, supporting programs from early-phase development through large-scale commercial manufacturing.
Hubert Scholze, PhD, holds a doctorate in Biochemistry from University of Technology Graz, Austria.
About Rezon Bio
Rezon Bio is a science-driven contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of mammalian biologics. Headquartered in Poland, Rezon Bio offers integrated solutions spanning cell line development, commercial drug substance manufacturing, and drug product development, with state-of-the-art facilities, world-class teams, and a proven track record of regulatory and commercial success. Grounded in Polpharma Biologic’s legacy of excellence in biosimilars development and manufacturing, Rezon Bio is committed to delivering value without compromise through innovation, collaboration, analytical excellence, and dedication to patients worldwide.
For more information, please visit: https://rezonbio.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260701630118/en/
Contacts
Media Contact:
Loukiani Chatzinasiou
loukiani.chatzinasiou@rezonbio.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna has received a favorable ruling in PriceRunner litigation, awarding damages of $1.97 billion1.7.2026 13:19:00 CEST | Press Release
Klarna Group plc (NYSE: KLAR) today announces that the court has ruled in PriceRunner’s favor, awarding $1.97 billion in damages in an antitrust case brought by PriceRunner against Google. The award compensates for lost revenue caused by Google's preferential treatment of its own comparison-shopping service over independent price-comparison services, conduct that also drives up costs for consumers. "When markets work well, everyone benefits. Consumers get higher quality at lower cost, companies stay focused on serving customers rather than defending position, and society is better off for it. This ruling supports a healthier, more competitive market for the way people compare products and services — and that is good for everyone who shops," said Dan Greaves, Head of Communications and Policy, Klarna. Klarna acquired PriceRunner in 2022 to add rich product discovery, price comparisons, and product reviews to the Klarna app, and drive high-intent traffic to retail partners. Klarna has si
Objectway Acquires Swiss Private Banking Technology Business From FNZ to Strengthen Its Pan-European Positioning1.7.2026 13:10:00 CEST | Press Release
Objectway, a global wealthtech partner for banking, wealth and asset management firms, today announced the acquisition from FNZ of their Swiss private banking technology business FNZ Switzerland SA (formerly operating as New Access). The business will now be operated under the Objectway Switzerland brand. Objectway welcomes a team of over 160 professionals, bringing their expertise and professionalism honed in developing innovative, award-winning solutions for over 40 private banks. The acquisition is a significant step in Objectway’s growth strategy, reinforcing its commitment to expanding its presence in key international wealth hubs such as Switzerland, Liechtenstein, Luxembourg, Monaco and the Bahamas, where the newly joined business already serves both domestic and international cross-border clients. The agreement further expands Objectway’s scalable core-to-digital capabilities supporting end-to-end private banking operations, while leveraging an international team and operationa
NIQ Completes Acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights Business, Expanding Digital Commerce Intelligence Capabilities1.7.2026 13:00:00 CEST | Press Release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that it has completed the acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights business. The acquired business operates in China under the YiMian (“一面”) brand and is a leading provider of eCommerce, social commerce, and digital shelf solutions. The acquisition expands NIQ’s capabilities across China and Southeast Asia and strengthens its ability to measure and understand consumer behavior across retail, eCommerce, social commerce, and digital environments — advancing NIQ’s mission to deliver The Full View™, the most complete understanding of consumer behavior across online and offline channels. It also enhances NIQ’s data and analytics foundation by expanding access to rich digital commerce signals that support the development of more advanced analytics and AI-powered solutions. By bringing together NIQ’s global intelligence, analytics, and retail measurement capabilities with the ac
Azalea Vision Awarded Prestigious EIC Accelerator Funding to Advance Smart Contact Lens into Clinical Development1.7.2026 13:00:00 CEST | Press Release
Azalea Vision, a Belgian healthtech company building the first medical-grade smart contact lens, today announced it has been selected for the European Innovation Council (EIC) Accelerator, the European Union’s flagship program for breakthrough, market-creating deep tech. Azalea is the only Belgian company selected in this round and will receive up to €7.5 million, including a non-dilutive €2.5 million grant and a planned €5 million equity investment from the EIC Fund, to advance its medical-grade smart contact lens platform into clinical development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701144267/en/ Azalea Vision Co-founder and CTO Andrés Vásquez Quintero undergoing an on-eye evaluation of the ALMA smart contact lens. Beyond the funding, the award is a strong external endorsement of Azalea’s technology and long-term vision. Built on its proprietary smart contact lens platform, Azalea’s smart lens is designed to
Croma-Pharma Announces FDA Approval of Obagi saypha® ChIQ™ in the United States1.7.2026 12:34:00 CEST | Press Release
Wrapping up the first half of 2026 with another important milestone, Croma-Pharma announces the FDA approval of Obagi saypha® ChIQ™ in the United States. Obagi saypha® ChIQ™ injectable hyaluronic acid gel is approved for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21. Developed and manufactured by Croma-Pharma and commercialized by Obagi Medical, a Waldencast company, in the U.S., ChIQ™ follows the approval of Obagi saypha® MagIQ™ in September 2025 and further broadens the availability of Croma's injectable aesthetic solutions in the United States. As demand for minimally invasive aesthetic treatments continues to grow, the approval broadens the range of treatment options available to healthcare professionals and patients seeking safe and natural-looking aesthetic outcomes. "With the approval of ChIQ™, we continue to strengthen the presence of our saypha® portfolio in the United States," said Andreas Prinz, Chief Executive Officer of Crom
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom